Insulin degludec has comparable control of blood glucose to insulin glargine [2-4]. Its long duration of action raises the possibility of three times weekly treatment regimes  which may be useful for certain types of care home setting or the older person living at home with medical and social support.
Degludecplus is a formulation of degludec with insulin aspart (rapid acting). Both Degludec and Degludecplus have been submitted for approval in Europe, USA and Japan.
1. Kalra S, Unnikrishnan AG, Baruah M, Kalra B. Degludec insulin: A novel basal insulin. Indian J Endocrinol Metab 2011 Jul;15(Suppl 1):S12–16.[cited 2012 Apr 1] Available from: http://www.ncbi.nlm.nih.gov/pubmed/21847448
2. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011 Mar;34(3):669–674.[cited 2011 Jun 13] Available from: http://www.ncbi.nlm.nih.gov/pubmed/21285389
3. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet 2011 Mar;377(9769):924–931.[cited 2011 Mar 15] Available from: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62305-7/abstract
4. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011 Mar;34(3):661–665.[cited 2012 Apr 1] Available from: http://www.ncbi.nlm.nih.gov/pubmed/21270174